Biomedical Research · us
Moving Cell Engineering Inside the Body: MIT Uses Nanoparticles to Guide NK Cells Against Cancer and Autoimmune Diseases
Lipid nanoparticles can deliver instructions for recognizing targets inside mice without first removing immune cells. Experiments in lymphoma and autoimmune hepatitis show therapeutic potential, but delivery precision, the risk of immune suppression, and the duration of efficacy remain hurdles before human use.
The challenges of cell therapy often arise before treatment even begins: immune cells must be removed, engineered, and then returned to the body. A research team at the Massachusetts Institute of Technology (MIT) is attempting to perform the engineering step inside the body, using lipid nanoparticles to deliver instructions to natural killer cells (NK cells). Published on October 13 in *Nature Biotechnology*, the study demonstrated therapeutic effects in mouse models of cancer and autoimmune disease, providing preclinical evidence for reducing cell manufacturing procedures outside the body.
The particles carry messenger RNA (mRNA) encoding chimeric antigen receptors (CARs). Once NK cells receive it, they can produce receptors that recognize specified targets. The central technical hurdle is getting the particles to find NK cells. To do this, the team attached antibody-derived ligands that recognize NK cell receptors to the particles’ surfaces, including a biparatopic design that binds to two sites on the same receptor. Both the paper’s abstract and Scienmag’s report state that the leading formulation enabled up to approximately 80% of NK cells in mice to successfully receive and express the delivered instructions. This figure represents delivery efficiency and cannot be interpreted as a treatment success rate.
The researchers first tested function using a CAR that recognizes CD19. This completely depleted B cells in the blood of healthy mice, demonstrating that the newly generated CAR NK cells could eliminate target cells. In a humanized mouse model that more closely approximates a human cellular environment, republished MIT research news reported that T-cell lymphoma tumors were eliminated after five nanoparticle injections, with effects similar to those of CAR NK cells manufactured outside the body and then infused back in. However, humanized mice still cannot fully reproduce patients’ immune environments.
Another set of experiments shifted the target to disease-causing immune cells. In a mouse model of autoimmune hepatitis, CAR NK cells that recognize the T-cell marker CD3 eliminated almost all autoreactive T cells. MIT research news also described repair of liver damage after a single injection. NK cells themselves do not express CD3, potentially allowing them to avoid the problem of engineered cells attacking one another when T cells are used to attack T cells. However, CD3 is not a marker exclusive to disease-causing T cells, and how to preserve normal immune defenses remains a question this approach must address.
The cancer experiments also showed that results varied by model. A supplementary summary of the same research on Bioengineer.org reported that three of five treated mice achieved complete remission in a melanoma model. This is a positive signal in a small sample, but it is insufficient to infer broad efficacy. The engineering in this study uses mRNA and is not designed to permanently integrate into the genome. Expression is temporary, meaning that how long the therapeutic effect lasts and whether repeated dosing is needed will both influence subsequent development.
### Background Context
Moving cell engineering inside the body is giving rise to different technological approaches. Basecamp recently raised $140 million to advance AI-designed gene insertion tools. MIT’s study, meanwhile, uses targeted nanoparticles to deliver mRNA, focusing on directly generating NK cells with therapeutic functions. Both seek to reduce procedures outside the body, but gene insertion and temporary mRNA expression pose different requirements for the duration of activity and safety assessment.
The clearest achievement so far is that the research team has completed a continuous sequence of validation inside animals, from delivering instructions to producing functional immune cells. To turn this into a therapy patients can use, researchers must still establish delivery efficiency in human NK cells, effects on non-target cells, and the long-term consequences of repeated dosing and immune cell depletion. The manufacturing process could be simplified, but clinical data are still needed to demonstrate safety, efficacy, and actual costs.